2020
Body Mass Index and Age Effects on Brain 11β-Hydroxysteroid Dehydrogenase Type 1: a Positron Emission Tomography Study
Bini J, Bhatt S, Hillmer AT, Gallezot JD, Nabulsi N, Pracitto R, Labaree D, Kapinos M, Ropchan J, Matuskey D, Sherwin RS, Jastreboff AM, Carson RE, Cosgrove K, Huang Y. Body Mass Index and Age Effects on Brain 11β-Hydroxysteroid Dehydrogenase Type 1: a Positron Emission Tomography Study. Molecular Imaging And Biology 2020, 22: 1124-1131. PMID: 32133575, PMCID: PMC7351613, DOI: 10.1007/s11307-020-01490-z.Peer-Reviewed Original ResearchConceptsBody mass indexPositron emission tomographyDehydrogenase type 1Mass indexObese individualsEnzyme 11β-hydroxysteroid dehydrogenase type 1Whole brainType 1Higher body mass indexPositron emission tomography studyVT valuesSevere Alzheimer's diseaseEmission tomography studiesSteroid stress hormonesAge-associated increaseMean whole brainSignificant age-associated increaseRegional distribution volumesVisceral adiposityInsulin resistanceActive cortisolExcess cortisolInactive cortisoneMemory dysfunctionParietal lobe
2016
Elevated Dopamine D2/3 Receptor Availability in Obese Individuals: A PET Imaging Study with [11C](+)PHNO
Gaiser EC, Gallezot JD, Worhunsky PD, Jastreboff AM, Pittman B, Kantrovitz L, Angarita GA, Cosgrove KP, Potenza MN, Malison RT, Carson RE, Matuskey D. Elevated Dopamine D2/3 Receptor Availability in Obese Individuals: A PET Imaging Study with [11C](+)PHNO. Neuropsychopharmacology 2016, 41: 3042-3050. PMID: 27374277, PMCID: PMC5101552, DOI: 10.1038/npp.2016.115.Peer-Reviewed Original ResearchConceptsBody mass indexVentral striatumObese individualsD2/3R availabilityOB individualsReward regionsSubstantia nigra/ventral tegmental areaDopamine D2/3 receptor availabilityNormal-weight individualsTreatment of obesityVentral tegmental areaNovel pharmacologic targetsD2/3 receptor availabilitySN/VTAAgonist tracersOverweight cohortMass indexWeight individualsTegmental areaBrain reward regionsAntagonist tracersPharmacologic targetReceptor availabilitySecondary analysisNW individuals
2013
Decreased norepinephrine transporter availability in obesity: Positron Emission Tomography imaging with (S,S)-[11C]O-methylreboxetine
Li CS, Potenza MN, Lee DE, Planeta B, Gallezot JD, Labaree D, Henry S, Nabulsi N, Sinha R, Ding YS, Carson RE, Neumeister A. Decreased norepinephrine transporter availability in obesity: Positron Emission Tomography imaging with (S,S)-[11C]O-methylreboxetine. NeuroImage 2013, 86: 306-310. PMID: 24121204, PMCID: PMC3947246, DOI: 10.1016/j.neuroimage.2013.10.004.Peer-Reviewed Original ResearchConceptsBody mass indexMultilinear reference tissue model 2Norepinephrine transporterNoradrenergic dysfunctionObese individualsLean individualsStructural MR scansBPND valuesNorepinephrine transporter availabilityReference tissue model 2Positron emission tomography (PET) imagingEmission Tomography ImagingPositron emission tomographyBrain norepinephrine transportersNE clearanceMass indexRaphe nucleusLocus coeruleusSynaptic availabilityObese peopleTransporter availabilityOccipital cortexComparison subjectsHealthy individualsObesity